Bosentan

CHEMBL957 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
551.6 g/mol
LogP
3.8
Phase
4

An endothelin receptor antagonist used to treat pulmonary arterial hypertension by relaxing and widening the blood vessels in the lungs. It blocks the action of endothelin, a potent substance that causes blood vessel constriction. It requires regular liver function monitoring and is teratogenic, requiring strict pregnancy prevention.

Peso molecular

551,6000 g/mol

LogP

3,80

TPSA

154,00 Ų

Regla de cinco de Lipinski

No cumple

Áreas terapéuticas

Mecanismo de acción

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO

InChI

InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)

Molecular Formula

C27H29N5O6S

HBD / HBA

2 / 11

Enlaces Rotables

11

Átomos Pesados

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An endothelin receptor antagonist used to treat pulmonary arterial hypertension by relaxing and widening the blood vessels in the lungs. It blocks the action of endothelin, a potent substance that causes blood vessel constriction. It requires regular liver function monitoring and is teratogenic, requiring strict pregnancy prevention.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Bosentan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL957. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 104865. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.